Belharah Therapeutics: A Startup Revolutionizing Small Molecule Drug Discovery

Belharah Therapeutics, a San Diego-based startup, is utilizing a unique approach to traditional small molecule drug discovery. By combining scientific work from Scripps Research with a new method of discovering protein targets that small molecules can hit, Belharah is poised to make a significant impact in the pharmaceutical industry. While scientists often focus on newer treatment paradigms, small molecules that can bind with disease proteins and be administered orally provide a compelling solution. Advances in small molecule chemistry are opening up new possibilities in targeting previously undrugable proteins like K-RAS found in various cancers. With CEO Jeff Yonker leading the way, Belharah is bringing innovation and expertise to the field of drug discovery.